查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470946

mRNA 平台市場：按 mRNA 類型、適應症、應用和最終用戶分類 - 2024-2030 年全球預測

mRNA Platform Market by mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA), Indication (Autoimmune Diseases, Cancer, Infectious Diseases), Application, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年mRNA平台市場規模為135.2億美元，2024年達163.3億美元，預計2030年將達到527.1億美元，複合年成長率為21.44%。

mRNA（傳訊RNA）平台是醫學和生物技術領域的一種新方法，主要用於疫苗和治療方法的開發。 mRNA 充當細胞中 DNA 和各種身體功能所必需的蛋白質之間的分子中介。 mRNA 平台利用合成 mRNA 引導細胞產生特定蛋白質，例如觸發免疫反應或刺激細胞修復，而不會改變細胞的 DNA。 mRNA 平台具有加速疫苗開發和生產的能力，由於全球對有效、快速生產疫苗的需求不斷成長，對 mRNA 平台的需求也不斷增加。只需改變疫苗中 mRNA 的序列，即可客製化 mRNA 療法來對抗從感染疾病到癌症等多種疾病。這種多功能性為針對各種病症的個人化醫療和治療方法開闢了新途徑。然而，mRNA疫苗和治療藥物需要超低溫儲存才能保持穩定性，這給配送帶來了挑戰，特別是在基礎設施有限的地區。將 mRNA 有效地遞送至細胞而不發生分解是一個相當大的障礙。研究人員不斷發現和改進脂質奈米顆粒和其他遞送方法來保護 mRNA，直到其到達目標細胞。除了預防性疫苗外，mRNA 技術也正在研究用於癌症治療、遺傳性疾病和自體免疫疾病等治療應用。

主要市場統計
基準年[2023] 135.2億美元
預測年份 [2024] 163.3億美元
預測年份 [2030] 527.1億美元
複合年成長率（%） 21.44%

mRNA 類型：核苷修飾的 mRNA 可以透過減少副作用和提高穩定性來平衡免疫反應的有效性。

核苷修飾的 mRNA 會改變 RNA 的組成部分（核苷），以逃避人體的自然防禦，這種防禦會快速分解 mRNA 或引發不必要的免疫反應。透過修飾這些核苷，科學家可以提高 mRNA 的穩定性和翻譯能力，從而使治療和疫苗訊息更有效地傳遞到人類細胞。這種類型的 mRNA 已廣泛用於 COVID-19 疫苗的開發，因為它能有效引發強烈且持久的免疫反應，且副作用最小。自我擴增的mRNA通常源自於正鏈RNA病毒的基因組，並且具有在宿主細胞內自我複製的獨特能力。這種放大過程意味著可以施用更小的劑量，這可能會降低製造成本並提高可用性。這種 mRNA 不僅編碼感興趣的抗原（例如，需要產生免疫反應的病毒部分），還編碼病毒複製機制，允許長期產生抗原，使其更能誘導強烈的免疫反應。未修飾的 mRNA 是用於醫學應用的最簡單的 mRNA 形式。它不像核苷修飾的 mRNA 那樣經歷核苷修飾。雖然這使得產生 mRNA 變得更容易，但未修飾的 mRNA 更容易分解，並可能誘導更強的先天免疫反應，為免疫系統提供強大的刺激，但也可能產生副作用。

最終用戶：製藥公司廣泛參與 mRNA 平台的行銷和許可。

醫院和診所主要使用基於 mRNA 的治療和疫苗作為患者照護服務的一部分。他們處於使用 mRNA 平台開發的疫苗的第一線，並在公共衛生工作中發揮關鍵作用，特別是在大流行期間。此外，醫院可以在專門護理下提供針對某些疾病的基於 mRNA 的治療方法。製藥公司正在為基於 mRNA 的藥物和疫苗的開發、測試和商業化做出重大貢獻。他們正在大力投資研發 (R&D)，以探索 mRNA 技術在治療多種疾病方面的潛力，包括感染疾病以及癌症和遺傳性疾病。這些公司處理成功的 mRNA治療方法的臨床試驗、監管核准和大規模生產的複雜過程。因此，製藥公司是推進 mRNA 平台並將新治療方法從實驗室推向市場的關鍵機構。研發機構和學術機構進行基礎研究，以了解細胞中 mRNA 的機制，探索改善 mRNA 遞送和穩定性的創新方法，並開發該技術的新應用。這些研究機構經常與製藥公司合作，提供進一步開發基於 mRNA 的治療方法所需的基礎知識。儘管這些機構不參與商業化過程，但它們在擴大對 mRNA 及其潛在應用的科學理解方面所發揮的作用是有價值的。

區域洞察

美洲，特別是美國和加拿大，由於醫療保健支出高、醫療保健基礎設施完善以及對研究和創新的高度重視，為 mRNA 平台呈現出成熟的格局。美洲地區是多家生物技術和製藥公司的所在地，這些公司經常投資研發項目，以提高 mRNA 平台的安全性、效率和性能。歐盟國家在支持 mRNA 研究和產品核可的法律規範方面處於領先地位。英國、德國和法國等國家在政府、學術界和私營部門之間的合作推動下擁有強大的生物技術部門。歐洲藥品管理局 (EMA) 在促進基於 mRNA 的治療方法的快速核准方面發揮著至關重要的作用。亞太地區是 mRNA 平台技術快速發展的地區，以中國、日本和印度為首。該地區人口眾多，對疫苗和治療方法（包括 mRNA 平台）有巨大需求。政府對改善醫療基礎設施的支持非常重要，而對先進治療方法的認知的提高為 mRNA 平台的擴展提供了重大機會。亞太地區作為疫苗和藥物治療藥物製造地的戰略地位也為加速 mRNA 平台的採用提供了有利的框架。

FPNV定位矩陣

FPNV定位矩陣對於評估mRNA平台市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對 mRNA 平台市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.mRNA平台市場的市場規模與預測是多少？

2. mRNA 平台市場預測期間需要考慮投資的產品、細分市場、應用程式和領域有哪些？

3.mRNA平台市場的技術趨勢和法規結構是什麼？

4.mRNA平台市場主要廠商的市場佔有率為何？

5.進入mRNA平台市場合適的形式和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病對治療藥物和疫苗的需求迅速增加
      • 需要縮短疫苗開發和商業化時間
    • 抑制因素
      • 製造和商業途徑最佳化的複雜性
    • 機會
      • 市值和公共資金的增加
      • 按需疫苗開發中 mRNA 技術的最佳化
    • 任務
      • 供應物流的監理風險和障礙較高
  • 市場區隔分析
    • mRNA類型：核苷修飾的mRNA能夠平衡免疫反應的有效性並減少副作用，並提高穩定性。
    • 最終用戶：製藥公司廣泛參與 mRNA 平台的行銷和許可
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 mRNA 平台市場：依 mRNA 類型

  • 核苷修飾的mRNA
  • 自我擴增mRNA
  • 未修飾的mRNA

第 7 章 mRNA 平台市場：依跡象分類

  • 自體免疫疾病
  • 癌症
  • 感染疾病
  • 罕見疾病
  • 呼吸系統疾病

第8章 mRNA 平台市場：依應用分類

  • 治療藥物
  • 疫苗

第 9 章 mRNA 平台市場：依最終用戶分類

  • 醫院/診所
  • 製藥公司
  • 研究/學術機構

第10章美洲mRNA平台市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太mRNA平台市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲/中東/非洲mRNA平台市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • VBI Vaccines Inc.在加拿大政府的支持下在mRNA疫苗技術上取得突破
    • 提升醫療保健的未來：mRNA 藥物的先鋒聯盟
    • Sensible Biotechnologies 和 Gingo Bioworks 組成策略聯盟，徹底改變 mRNA 生產
  • 戰略分析和建議

第14章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-374DB5A05ED7

[194 Pages Report] The mRNA Platform Market size was estimated at USD 13.52 billion in 2023 and expected to reach USD 16.33 billion in 2024, at a CAGR 21.44% to reach USD 52.71 billion by 2030.

The mRNA (messenger RNA) platform is a novel approach in the field of medicine and biotechnology, primarily utilized for the development of vaccines and therapeutics. mRNA serves as a molecular intermediary between the DNA in cells and the proteins that are essential for various bodily functions. The mRNA platform leverages synthetic mRNA to instruct cells to produce specific proteins that can trigger an immune response or stimulate cell repair without altering the cell's DNA. The ability of mRNA platforms to accelerate the development and production of vaccines and the rising global need to effectively and quickly produce vaccines has driven the need for mRNA platforms. mRNA therapies can be tailored to fight a wide array of diseases, from infectious diseases to cancer, by simply modifying the mRNA sequence the vaccines carry. This versatility opens up new avenues in personalized medicine and treatments for various conditions. However, mRNA vaccines and therapeutics require ultra-cold storage to remain stable, presenting logistical challenges in distribution, particularly in regions with limited infrastructure. Efficiently delivering mRNA into cells without degradation is a considerable hurdle. Researchers are continuously working on finding and improving lipid nanoparticles and other delivery methods to protect the mRNA until it reaches the target cells. Beyond preventive vaccines, mRNA technology is being explored for therapeutic applications, including cancer treatment, genetic disorders, and autoimmune diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 13.52 billion
Estimated Year [2024] USD 16.33 billion
Forecast Year [2030] USD 52.71 billion
CAGR (%) 21.44%

mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability

Nucleoside-modified mRNA involves the alteration of RNA building blocks (nucleosides) to evade the body's natural defenses, which might otherwise rapidly degrade the mRNA or trigger an unwanted immune response. By modifying these nucleosides, scientists can enhance the stability and translational capacity of the mRNA, making it more effective in delivering the therapeutic or vaccine message to the body's cells. This type of mRNA has been widely used in developing COVID-19 vaccines due to its efficiency in producing a strong and lasting immune response with minimal side effects. Self-amplifying mRNA, often derived from the genome of positive-strand RNA viruses, has the unique ability to replicate itself within the host cells. This amplification process means that smaller doses can be administered, potentially reducing production costs and improving accessibility. In addition to encoding the antigen of interest (such as parts of a virus against which an immune response is desired), this mRNA also encodes the viral replication machinery, enabling the prolonged production of the antigen and thereby inducing a stronger and longer-lasting immune response. Unmodified mRNA is the most straightforward form of mRNA used in medical applications. It does not undergo the nucleoside modifications seen in nucleoside-modified mRNA. While this simplifies its production, unmodified mRNA is more susceptible to degradation and may induce stronger innate immune responses, providing a potent stimulant for the immune system but also potentially leading to adverse effects.

End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms

Hospitals and clinics primarily use mRNA-based treatments and vaccines as part of their patient care services. They are at the forefront of administering vaccines developed using the mRNA platform, playing a crucial role in public health initiatives, especially during pandemics. Additionally, mRNA-based therapies for certain diseases might be provided in hospital settings under specialized care. Pharmaceutical companies are instrumental in the development, testing, and commercialization of mRNA-based drugs and vaccines. They invest heavily in research and development (R&D) to explore the potential of mRNA technology in treating a wide array of diseases, beyond just infectious diseases to include cancer and genetic disorders. These companies handle the complex processes of clinical trials, regulatory approvals, and mass production of successful mRNA treatments. Thus, pharmaceutical companies are key institutions in advancing the mRNA platform and bringing new therapies from the lab to the market. Research and academic institutions conduct fundamental research to understand the mechanism of mRNA within the cell, explore innovative approaches to improve mRNA delivery and stability, and develop new applications for this technology. These institutions often collaborate with pharmaceutical companies and provide the foundational knowledge necessary for further development of mRNA-based treatments. While they are not involved in the commercialization process, their role in expanding the scientific understanding of mRNA and its potential applications is valuable.

Regional Insights

The Americas, particularly the United States and Canada, present a mature landscape for the mRNA platform, driven by the high healthcare expenditure, sophisticated healthcare infrastructure, and a strong focus on research and innovation. The Americas region is characterized by the presence of several biotechnology and pharmaceutical companies that frequently invest in R&D programs to improve the safety, efficiency, and performance of mRNA platforms. EU countries lead in regulatory frameworks supporting mRNA research and product approvals. Nations such as the U.K., Germany, and France have strong biotech sectors that are propelled by collaborative efforts between governments, academia, and private sectors. The European Medicine Agency (EMA) plays a pivotal role in facilitating the swift approval of mRNA-based treatments. APAC region is a rapidly evolving landscape for mRNA platform technologies driven by China, Japan, and India. The region's significant population base presents a vast need for vaccines and therapeutic treatments, including mRNA platforms. Government support for improving the healthcare infrastructure notably and a growing awareness of advanced treatment modalities present significant opportunities for the expansion of mRNA platforms. APAC's strategic position as a manufacturing hub for vaccines and drug therapeutics also serves to create a conducive framework for driving the adoption of mRNA platforms.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the mRNA Platform Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the mRNA Platform Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Accanis Biotech F&E GmbH & Co KG, Aldevron, LLC by Danaher Corporation, Arcturus Therapeutics, Inc., Argos Therapeutics, Inc., AstraZeneca plc, Avectas Limited, BioNTech SE, Catalent, Inc., CRISPR Therapeutics AG, CureVac N.V., Daiichi Sankyo, Dicerna Pharmaceuticals, Inc by Novo Nordisk A/S, eTheRNA, ethris GmbH, Gritstone bio, In-Cell-Art, Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Tiba Biotech LLC, and Verve Therapeutics.

Market Segmentation & Coverage

This research report categorizes the mRNA Platform Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • mRNA Type
    • Nucleoside-Modified mRNA
    • Self-Amplifying mRNA
    • Unmodified mRNA
  • Indication
    • Autoimmune Diseases
    • Cancer
      • Personalized Treatment
      • Single Cancer Focussed
    • Infectious Diseases
    • Rare Diseases
    • Respiratory Diseases
  • Application
    • Therapeutics
    • Vaccines
  • End-User
    • Hospitals & Clinics
    • Pharmaceutical Companies
    • Research & Academic Institutiions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the mRNA Platform Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the mRNA Platform Market?

3. What are the technology trends and regulatory frameworks in the mRNA Platform Market?

4. What is the market share of the leading vendors in the mRNA Platform Market?

5. Which modes and strategic moves are suitable for entering the mRNA Platform Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in demand of therapies and vaccines due to the infectious diseases
      • 5.1.1.2. Need to reduce vaccine development and commercialization timeline
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity in optimising manufacturing and commercial pathways
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased market capitalization and public funding
      • 5.1.3.2. mRNA technology optimization on development of on-demand vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. High regulatory risk and hurdles in supply logistics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability
    • 5.2.2. End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. mRNA Platform Market, by mRNA Type

  • 6.1. Introduction
  • 6.2. Nucleoside-Modified mRNA
  • 6.3. Self-Amplifying mRNA
  • 6.4. Unmodified mRNA

7. mRNA Platform Market, by Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Cancer
  • 7.4. Infectious Diseases
  • 7.5. Rare Diseases
  • 7.6. Respiratory Diseases

8. mRNA Platform Market, by Application

  • 8.1. Introduction
  • 8.2. Therapeutics
  • 8.3. Vaccines

9. mRNA Platform Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals & Clinics
  • 9.3. Pharmaceutical Companies
  • 9.4. Research & Academic Institutiions

10. Americas mRNA Platform Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific mRNA Platform Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa mRNA Platform Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. VBI Vaccines Inc.'s Groundbreaking Advancement in mRNA Vaccine Technology with Government of Canada Support
    • 13.3.2. Elevating the Future of Healthcare: The Pioneering Alliance for mRNA Medicines
    • 13.3.3. Sensible Biotechnologies and Ginkgo Bioworks Forge Strategic Alliance for Revolutionizing mRNA Production
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. MRNA PLATFORM MARKET RESEARCH PROCESS
  • FIGURE 2. MRNA PLATFORM MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MRNA PLATFORM MARKET DYNAMICS
  • FIGURE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MRNA PLATFORM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL MRNA PLATFORM MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNMODIFIED MRNA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNMODIFIED MRNA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL MRNA PLATFORM MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL MRNA PLATFORM MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL MRNA PLATFORM MARKET SIZE, BY PERSONALIZED TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL MRNA PLATFORM MARKET SIZE, BY PERSONALIZED TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL MRNA PLATFORM MARKET SIZE, BY SINGLE CANCER FOCUSSED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL MRNA PLATFORM MARKET SIZE, BY SINGLE CANCER FOCUSSED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 328. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 335. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. NIGERIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 338. NIGERIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 339. NIGERIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 340. NIGERIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 341. NIGERIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 342. NIGERIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 343. NIGERIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 344. NIGERIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 345. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 346. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 347. NORWAY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. NORWAY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. NORWAY MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 350. NORWAY MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 351. NORWAY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 352. NORWAY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 353. NORWAY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 354. NORWAY MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 355. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 356. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 357. POLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 358. POLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 359. POLAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 360. POLAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 361. POLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 362. POLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 363. POLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 364. POLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 365. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 366. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 367. QATAR MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 368. QATAR MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 369. QATAR MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 370. QATAR MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 371. QATAR MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 372. QATAR MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 373. QATAR MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 374. QATAR MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 375. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 376. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 377. RUSSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 378. RUSSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 379. RUSSIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 380. RUSSIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 381. RUSSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 382. RUSSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-203